Lyell Immunopharma, Inc.
Clinical trials sponsored by Lyell Immunopharma, Inc., explained in plain language.
-
Engineered immune cells take on Hard-to-Treat colon cancer
Disease control Recruiting nowThis early-phase study tests a new treatment called GCC19CART for people with advanced colorectal cancer that has come back or not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target a protein found on cancer cells. The main goals …
Phase: PHASE1 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 26, 2026 04:01 UTC
-
New Dual-Targeting CAR t therapy aims to outperform standard treatment for blood cancer
Disease control Recruiting nowThis Phase 3 trial tests a new CAR T-cell therapy called ronde-cel, which targets two proteins (CD19 and CD20) on lymphoma cells, against the standard single-target CAR T therapy. The study involves 400 adults with large B-cell lymphoma that has returned or not responded after in…
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 26, 2026 04:00 UTC
-
Double-Target attack: new CAR t therapy takes on tough lymphoma
Disease control Recruiting nowThis study tests a new treatment called ronde-cel for people with aggressive B-cell lymphoma that has come back or not improved after at least two prior therapies. The treatment uses a patient's own immune cells, modified to target two different markers on cancer cells. The goal …
Phase: PHASE1, PHASE2 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC